 ;templatestyles src="Infobox drug/styles.css"/ ;
}}|[[Category:Infobox drug articles with contradicting parameter input| ]]}}{{#if:|{{#if:Investigational
 ||[[Category:Drugs with no legal status]]}}{{#if:{{#ifeq:{{lc:}} ||[[Category:Infobox drug articles without vaccine target]]}}{{#if: |[[Category:Drug has EMA link]]}}{{#if: |[[Category:Chemicals having QID set|*]]}}{{#if: |[[Category:Chemicals (indexed) having QID set|*]]}}{{#ifeq:|changed|[[Category:Drugboxes which contain changes to verified fields]]
}}{{#ifeq:|changed|[[Category:Drugboxes which contain changes to watched fields]]
Evobrutinib is an experimental drug being studied for the treatment of [[encephalomyelitis]] and [[multiple sclerosis]]. It is an [[enzyme inhibitor|inhibitor]] of [[Bruton's tyrosine kinase]].
References.
 ;templatestyles src="Reflist/styles.css" / ;
[[Category:Kinase inhibitors]]
[[Category:Aminopyrimidines]]
[[Category:Acrylamides]]
[[Category:Diphenyl ethers]]
[[Category:Piperidines]]